A1 Refereed original research article in a scientific journal
Risk factors associated with IgG seropersistence to Chlamydia trachomatis and Mycoplasma genitalium
Authors: Koskela, Nea; Butt, Julia; Michels, Birgitta; Syrjänen, Kari; Grenman, Seija; Waterboer, Timo; Syrjänen, Stina; Louvanto, Karolina
Publisher: Cambridge University Press
Publication year: 2025
Journal: Epidemiology and Infection
Journal name in source: Epidemiology and Infection
Article number: e104
Volume: 153
First page : 1
Last page: 7
ISSN: 0950-2688
eISSN: 1469-4409
DOI: https://doi.org/10.1017/S095026882500007X
Web address : https://doi.org/10.1017/S095026882500007X
Self-archived copy’s web address: https://research.utu.fi/converis/portal/detail/Publication/499692946
Sexually transmitted infections caused by Chlamydia trachomatis (Ct) and Mycoplasma genitalium (Mg) have significant implications both at the individual and societal levels. Our study evaluated various co-factors associations with persistent serum IgG-antibodies to Ct and Mg. 329 pregnant women and 135 men from the Finnish Family HPV study were analysed for serum IgG-antibodies of pGP3 for Ct and MgPa and rMgPa for Mg using multiplex serology. Seropersistence to both Ct and Mg was more common in women (30.4% and 13.3%) than in men (17.4% and 5.3%). The number of lifetime sexual partners above 10, practice of anal sex, and history of diagnosed Ct were associated with seropersistence to Ct in women, adjusted ORs 5.6 (95%CI 1.39-22.29), 15.3 (95%CI 1.18-197.12) and 18.0 (95%CI 5.59-57.92), respectively. The increasing number of partners before the age f 20 was the main risk factor for seropersistence among women with Mg, adjusted OR range from 5.0 to 12.3 (95%CI range 1.17-100.90) and in men only with 6 to 10 partners for Ct, adjusted OR 12.6 (95%CI 1.55-102.49). To conclude, persistent Ct antibodies were associated with various sexual activities, and Mg seropositivity was mainly associated with increased sexual activity in early 34 adulthood.
Downloadable publication This is an electronic reprint of the original article. |
Funding information in the publication:
Since its onset in 1998, the FFHPV study has been financially supported by the Academy of Finland
308 [SS, KL]; Päivikki and Sakari Sohlberg Foundation [SS, SG, KL]; Sigrid Jusélius Foundation [KL];
309 and the Finnish Medical Foundation [KL]. The authors declare no conflict of interest.